Document registry — page 22
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the effect of Teduglutide compared with the comparator used in its…
Moderate28 Jun 2025 -
In the population defined for obstructive sleep apnoea with obesity, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with…
High27 Jun 2025 -
GLP-1 receptor agonist (cAMP-biased, acylated). Selective GLP-1 receptor agonism with a reported bias towards Gαs-coupled cyclic-AMP signalling. Whether signalling bias translates into a clinically…
Low27 Jun 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation…
Moderate26 Jun 2025 -
Phase 1 ascending dose, phase 1 study of Exenatide in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low25 Jun 2025 -
Consultation on the draft of CEI-MS-09, which specifies the performance a determination must achieve for physical quality and states what the resulting figure does not…
24 Jun 2025 -
Record of documents ratified in the 2025 Q2 assessment cycle.
22 Jun 2025 -
Consultation on the draft monograph for Selank, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
22 Jun 2025 -
What is the evidence for thymic peptides in chronic viral hepatitis, sepsis and non-specific immune support?
Low17 Jun 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Orforglipron compared with its…
Moderate16 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity and type 2 diabetes randomising 1,206 participants…
Moderate16 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low15 Jun 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Jun 2025 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low14 Jun 2025 -
Consultation on the draft safety review of the rodent thyroid C-cell signal observed with glucagon-like peptide-1 receptor agonists and its relevance to humans. The…
13 Jun 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with CagriSema (cagrilintide with semaglutide)…
Moderate12 Jun 2025 -
Endogenous decapeptide, KISS1 receptor agonist. Kisspeptin acts on KISS1 receptors on hypothalamic gonadotropin-releasing hormone neurons to stimulate GnRH secretion, and thereby luteinising…
Low11 Jun 2025 -
Consultation on the comparison table that presents supplier dossiers side by side. The draft table shows only fields verified from a document the Institute holds, and…
10 Jun 2025 -
Randomised crossover, phase 1 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low08 Jun 2025 -
Consultation on the draft of this methodological review, which registers the question: To what extent does a change in body weight predict a change in the clinical…
03 Jun 2025 -
Randomised, open-label, active-controlled, phase 3 study of Tirzepatide in obesity randomising 751 participants over 72 weeks. Primary result: Mean change −20.2 % with…
High28 May 2025 -
What clinical evidence supports the uses under which growth-hormone secretagogues are supplied for research?
Very low26 May 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in mash randomising 1,197 participants over 72 weeks for part 1. Primary result: Resolution in…
Moderate26 May 2025 -
In adults with obesity and without type 2 diabetes, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on percentage change in body…
High23 May 2025 -
Determination of water content in lyophilised peptides by coulometric Karl Fischer titration
High23 May 2025 -
Single-arm open-label, phase 3 study of Orforglipron in obesity and type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported…
Very low23 May 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low23 May 2025 -
Consultation on the draft monograph for TB-500, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
22 May 2025 -
What proportion of certificates of analysis supplied with research peptides contain the fields required to interpret the reported purity figure?
Moderate20 May 2025 -
GIP receptor antagonist and GLP-1 receptor agonist conjugate (antibody–peptide). GLP-1 receptor agonism supplies appetite suppression; GIP receptor antagonism is proposed to act on adipose tissue and central pathways in…
Low19 May 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Retatrutide compared with the comparator used in its contributing trials on the…
Moderate17 May 2025 -
In the population defined for primary mitochondrial myopathy and bioenergetic disorders, what is the incidence of adverse events leading to discontinuation with SS-31…
Moderate14 May 2025 -
Randomised, double-blind, placebo-controlled study of DSIP in sleep over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low14 May 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Survodutide in obesity randomising 387 participants over 46 weeks. Primary result: Mean change −18.7 % at…
Moderate12 May 2025 -
Observational study of Semax in cognition over not recorded. Primary result: As above. The Institute grades all claims for this compound very low certainty for absence…
12 May 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its…
High08 May 2025 -
Phase 1 ascending dose, phase 1 study of Amycretin in obesity randomising 125 participants over up to 36 weeks. Primary result: Exploratory weight reduction of…
Low04 May 2025 -
Consultation on the print and archival format for Institute documents: what a printed copy must carry so that it remains checkable when detached from the site, and what…
02 May 2025 -
Consultation on the terms governing the Institute's calculators. The draft states that a calculator implements a published formula, that it holds no user data, and that…
01 May 2025 -
In adults with type 2 diabetes, does tirzepatide achieve greater glycaemic and weight effect than semaglutide?
High26 Apr 2025
page 22 of 41